Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial
Jastreboff A, Kaplan L, Frias J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M, Blüher M. Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial. Diabetologie Und Stoffwechsel 2024, 19: s77-s78. DOI: 10.1055/s-0044-1785389.Peer-Reviewed Original ResearchPhase 2 trialTriple receptor